Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study - PubMed (original) (raw)
Randomized Controlled Trial
. 2006 Feb 1;23(3):365-70.
doi: 10.1111/j.1365-2036.2006.02772.x.
Affiliations
- PMID: 16422995
- DOI: 10.1111/j.1365-2036.2006.02772.x
Free article
Randomized Controlled Trial
Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study
D Broekaert et al. Aliment Pharmacol Ther. 2006.
Free article
Abstract
Background Tricyclic antidepressants, which have multiple pharmacological influences, have a therapeutic effect in non-cardiac chest pain, but selective serotonin reuptake inhibitors have a single pharmacological effect. Aim To evaluate the acute effect of citalopram on oesophageal hypersensitivity. Methods On two separate occasions, 10 healthy subjects (seven men, mean age 25 years) with established oesophageal hypersensitivity, underwent oesophageal manometry with evaluation of mechanical and chemical sensitivity. Subjects received placebo or citalopram 20 mg i.v. in a randomized, crossover, double-blind fashion. Results Citalopram did not alter oesophageal motility. Citalopram significantly increased the threshold inducing first perception (4.6+/-0.3 vs. 6.7+/-0.4 mL, P<0.005) and discomfort (8.6+/-0.4 vs. 9.9+/-0.6 mL, P<0.01) during balloon distention. It also significantly prolonged the acid perfusion time to induce perception of heartburn (6.0+/-0.9 vs. 10.7+/-0.6 min, P<0.005) and discomfort (12.2+/-0.8 vs. 16.7+/-0.7 mL, P<0.001). Seven subjects experienced a retrosternal sensation during edrophonium provocation with placebo, and this was reduced to two of 10 after citalopram (P=0.02). Conclusions Acute administration of citalopram significantly lowers chemical and mechanical oesophageal sensitivity in oesophageal hypersensitivity, without altering the motility.
Similar articles
- A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache.
Bendtsen L, Jensen R, Olesen J. Bendtsen L, et al. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90. doi: 10.1136/jnnp.61.3.285. J Neurol Neurosurg Psychiatry. 1996. PMID: 8795600 Free PMC article. Clinical Trial. - Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers - a placebo-controlled study.
Chua YC, Ng KS, Sharma A, Jafari J, Surguy S, Yazaki E, Knowles CH, Aziz Q. Chua YC, et al. Aliment Pharmacol Ther. 2012 Feb;35(3):319-26. doi: 10.1111/j.1365-2036.2011.04955.x. Epub 2011 Dec 27. Aliment Pharmacol Ther. 2012. PMID: 22211824 Clinical Trial. - Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study.
Viazis N, Keyoglou A, Kanellopoulos AK, Karamanolis G, Vlachogiannakos J, Triantafyllou K, Ladas SD, Karamanolis DG. Viazis N, et al. Am J Gastroenterol. 2012 Nov;107(11):1662-7. doi: 10.1038/ajg.2011.179. Epub 2011 May 31. Am J Gastroenterol. 2012. PMID: 21625270 Clinical Trial. - Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials.
Keller MB. Keller MB. J Clin Psychiatry. 2000 Dec;61(12):896-908. J Clin Psychiatry. 2000. PMID: 11206593 Review. - Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
Mochcovitch MD, Nardi AE. Mochcovitch MD, et al. Expert Rev Neurother. 2010 Aug;10(8):1285-93. doi: 10.1586/ern.10.110. Expert Rev Neurother. 2010. PMID: 20662754 Review.
Cited by
- Diagnosis and Management of Noncardiac Chest Pain.
Li T, Jawish MA, Badurdeen D, Koop AH. Li T, et al. Gastroenterol Hepatol (N Y). 2024 Oct;20(9):533-541. Gastroenterol Hepatol (N Y). 2024. PMID: 39484001 Free PMC article. - General and anxiety-linked influences of acute serotonin reuptake inhibition on neural responses associated with attended visceral sensation.
Livermore JJA, Skora LI, Adamatzky K, Garfinkel SN, Critchley HD, Campbell-Meiklejohn D. Livermore JJA, et al. Transl Psychiatry. 2024 Jun 6;14(1):241. doi: 10.1038/s41398-024-02971-3. Transl Psychiatry. 2024. PMID: 38844469 Free PMC article. Clinical Trial. - Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders.
Alkhowaiter SS, Alshahrani AH, Almarzouqi HF, Alonazi GK, Alhawassi TM, AlRasheed MM. Alkhowaiter SS, et al. Front Pharmacol. 2023 May 22;14:1131354. doi: 10.3389/fphar.2023.1131354. eCollection 2023. Front Pharmacol. 2023. PMID: 37284319 Free PMC article. - Gastroesophageal Reflux Disease: Pathophysiology and New Treatment Trends.
Kasugai K, Ogasawara N. Kasugai K, et al. Intern Med. 2024 Jan 1;63(1):1-10. doi: 10.2169/internalmedicine.1551-23. Epub 2023 Mar 15. Intern Med. 2024. PMID: 36927966 Free PMC article. - Pathophysiology and treatment options for gastroesophageal reflux disease: looking beyond acid.
Sharma P, Yadlapati R. Sharma P, et al. Ann N Y Acad Sci. 2021 Feb;1486(1):3-14. doi: 10.1111/nyas.14501. Epub 2020 Oct 4. Ann N Y Acad Sci. 2021. PMID: 33015827 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical